Three classes of anti-hyperglycaemic medications are distinguished by their urinary sodium excretion-enhancing and blood pressure-lowering actions: long-acting glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors. Yet, these drugs exert different effects on macrovascular risk. Glucagon-like peptide-1 receptor agonists reduce atherosclerotic thromboembolic events, but have little effect on heart failure; sodium-glucose co-transporter-2 inhibitors decrease the occurrence of heart failure, but have minimal effect on myocardial infarction and stroke; and dipeptidyl peptidase-4 inhibitors do not ameliorate either atherosclerotic thromboembolic events or heart failure. Similarly, the three classes of drugs differ in their early effects on renal function. Dipeptidyl peptidase-4 inhibitors produce a small decrease in renal function that persists for the duration of treatment, and they do not prevent serious adverse renal events. For glucagon-like peptide-1 receptor agonists, a small early decrease in renal function persists for 2 years and is superseded by a small improvement in renal function, with no effect on renal outcomes. In contrast, an initial decrease in glomerular filtration with sodium-glucose co-transporter-2 inhibitors persists for only 1 year and is superseded by a durable improvement in renal function and a reduced risk of serious adverse renal events. These differences may be related to different actions on the proximal tubular reabsorption of sodium, and thereby, on glomerular hyperfiltration. Anti-hyperglycaemic drugs that have natriuretic actions differ markedly in their ability to modulate macrovascular and microvascular risk. These contrasting profiles cannot be predicted by their effects on blood glucose or blood pressure.
Introduction
Three classes of anti-hyperglycaemic medications are distinguished by their actions in promoting urinary sodium excretion and lowering blood pressure. Long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide, semaglutide and exenatide) produce prolonged stimulation of the GLP-1 receptor [1] . Drugs that inhibit dipeptidyl peptidase-4 (DPP-4; e.g. sitagliptin, saxagliptin and alogliptin) enhance the actions of endogenous GLP-1, but may also augment the effects of non-GLP-1 peptides that are normally degraded by DPP-4 [2] . Sodium-glucose co-transporter-2 (SGLT2) inhibitors (e.g. empagliflozin, dapagliflozin and canagliflozin) block the reabsorption of both glucose and sodium in the proximal tubule [3] . All three classes of drugs exert natriuretic effects that contribute to their ability to lower blood pressure [3] [4] [5] . The ability to promote urinary sodium excretion distinguishes these newer agents from many older anti-hyperglycaemic medications, which often caused sodium retention and had minimal effects on blood pressure [6, 7] . When added to their ability to lower blood glucose, the actions of GLP-1 receptor agonists, DPP-4 inhibitors and SGLT2 inhibitors in causing natriuresis and lowering blood pressure might be expected to augment the potential of these drugs to reduce the risk of important macrovascular events and ameliorate the risk of diabetic nephropathy [8, 9] .
Contrasting macrovascular effects of natriuretic anti-hyperglycaemic drugs
Despite their shared actions of lowering blood glucose and blood pressure and promoting sodium excretion, the three classes of anti-hyperglycaemic medications exerted different effects on the risk of macrovascular events in large-scale trials in people with clinically stable Type 2 diabetes (Table 1) . GLP-1 receptor agonists reduce the likelihood of atherosclerotic thromboembolic events (by 10-25%), but have little effect on the risk of new-onset heart failure [10] [11] [12] . One GLP-1 receptor agonist (liraglutide) has been reported to worsen the clinical course of people with preexisting heart failure [13, 14] . In contrast, SGLT2 inhibitors primarily act to reduce the occurrence of new-onset heart failure and deaths related to heart failure (by 30-40%), but have minimal effect on the risk of non-fatal myocardial infarction and non-fatal stroke [15, 16] . One SGLT2 inhibitor (canagliflozin) has been reported to increase the risk of lower limb amputation [16] . Finally, despite continuous treatment for 3-4 years in adequately powered trials, DPP-4 inhibitors do not ameliorate the risk of either atherosclerotic thromboembolic events or the development of heart failure [17, 18] . Two DPP-4 inhibitors, saxagliptin and alogliptin, have been associated with an increased risk of hospitalization for heart failure [19] . The distinct profiles of these three classes of drugs cannot be explained by the magnitude of their blood glucose-lowering effects ( Table 1 ).
The mechanisms underlying these different effects on macrovascular risk have not been fully elucidated, but the three classes of drugs can exert direct actions on the heart that are not mediated through changes in blood glucose. Specifically, SGLT2 inhibitors may inhibit the deleterious consequences of an activated sodium-hydrogen exchanger in the diabetic myocardium [20] . Incretin-based drugs do not exert such a benefit, and in fact, may exacerbate the cardiomyopathic process by virtue of their actions of increasing heart rate and increasing cyclic AMP (Fig.1 ) [21] . Additionally, DPP-4 inhibitors potentiate the effect of endogenous stromal cell-derived factor-1 (SDF-1) [5] , which may, in turn, adversely affect cardiac remodelling by promoting activation of the sympathetic nervous system as well as cardiac inflammation and fibrosis [22, 23] .
In addition, signalling through the GLP-1 receptor may have direct effects of inhibiting atheroma formation and promoting plaque stability [24, 25] , which may underlie the ability of long-acting receptor agonists to reduce the occurrence of thromboembolic events (Fig. 1) [11] [12] [13] . These benefits are likely to be more pronounced with long-acting GLP-1 receptor agonists than with DPP-4 inhibitors because of the ability of the former to produce supraphysiological stimulation of the GLP-1 receptor, whereas incretin signalling produced by DPP-4 inhibitors relies on the actions of endogenous physiological levels of GLP-1 [2, 5] . In addition, the effect of DPP-4 (but not GLP-1 receptor agonists) to potentiate the actions of the proinflammatory chemokine SDF-1 can negate the benefits of GLP-1 on atherosclerotic plaque stability [5, 26, 27] . Simultaneous enhancement of the opposing effects of GLP-1 and SDF-1 on the biology of diseased coronary arteries may explain why DPP-4 inhibitors have not altered the early risk of myocardial infarction and stroke in large-scale clinical trials [16, 17] .
Contrasting microvascular effects of natriuretic anti-hyperglycaemic drugs
In addition to their different effects on macrovascular risk, natriuretic anti-hyperglycaemic drugs may also differ with respect to their influence on microvascular risk. The largescale cardiovascular outcome trials with GLP-1 receptor agonists, DPP-4 inhibitors and SGLT2 inhibitors were not designed to examine the effect of treatment on the risk of hyperglycaemia-related retinopathy, nephropathy or neuropathy. Changes in microvascular risk in diabetes typically requires interventions that are sustained for 10 years or more [28] , whereas cardiovascular outcome trials have followed participants for a median duration of <4 years. Nevertheless, hyperglycaemia can directly promote albuminuria [29] and, commensurate with their shared antihyperglycaemic action, all three natriuretic antidiabetes drugs can ameliorate albuminuria [11] [12] [13] [14] [15] [16] [17] 30, 31] .
Despite their similar actions on albuminuria, the three classes of natriuretic anti-hypertensive hypoglycaemic drugs exert different effects on the course of chronic diabetic kidney disease, even during a follow-up period of only a few years ( Table 1) . Initiation of therapy with all three classes of drugs produces a small decrease in GFR, which can be seen as early as 4 weeks after initiation of treatment [16, [30] [31] [32] . Yet, the fate of this early decline in glomerular function varies meaningfully across the three classes of drugs. With respect to DPP-4 inhibitors, the small decrease in renal function persists for up to 4 years, and these drugs do not reduce the risk of serious adverse renal events during this time frame [16, 31] . In the case of GLP-1 receptor agonists, a small early decrease in renal function persists for 2 years and is superseded by a small improvement in renal function [30] . Long-acting GLP-1 receptor agonists have not been shown to reduce the risk of serious adverse renal effects [30] .
What's new?
• Although they promote sodium excretion and lower blood pressure, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors exert different effects on macrovascular and microvascular events.
• GLP-1 receptor agonists reduce atherosclerotic thromboembolic events, but not risk of heart failure; SGLT2 inhibitors decrease the risk of heart failure but not of myocardial infarction or stroke; and DPP-4 inhibitors have neither benefit and may increase the risk of heart failure.
• SGLT2 inhibitors produce a durable and meaningful improvement in renal function, which is accompanied by a reduced risk of serious adverse renal events. In marked contrast, when SGLT2 inhibitors are administered to people with Type 2 diabetes, the initial decrease in GFR seen after initiation of treatment persists for only 1 year and is superseded by a meaningful improvement in renal function during the second, third and fourth years of followup [16, 32] . Short-term withdrawal of the drug after longterm treatment reveals even larger between-group differences in renal function, indicating that SGLT2 inhibitors lead to durable benefits on the kidney that are not dependent on their continued pharmacological action [32] . Importantly, this long-term beneficial effect on GFR is accompanied by a reduced risk of serious adverse renal events, including a decreased likelihood of doubling of serum creatinine or the need for renal replacement therapy [15, 16, 32] . The pattern of this response mimics that seen when inhibitors of the renin-angiotensin system are given to people with diabetes; an initial short-term decline in glomerular filtration is superseded by an improvement in renal function and a reduced risk of progression to end-stage kidney disease [33] .
Mechanisms by which natriuretic anti-hyperglycaemic drugs influence the rate of decline in glomerular function in Type 2 diabetes
What mechanisms can account for differences in the effects of natriuretic antidiabetes medications on the kidney? Because hyperglycaemia can cause glomerular hyperfiltration [34] , initiation of treatment with glucose-lowering drugs often leads to a small early reduction in glomerular function [30] [31] [32] 35] ; however, to exert an important early effect to prevent the progressive and irreversible loss of nephrons in diabetes, some have hypothesized that therapeutic measures must act to minimize glomerular hyperfiltration directly [36] .
Vallon et al. [37, 38] have postulated that the hyperfiltration seen in diabetes results from the hyper-reabsorption of sodium in the early proximal tubule, which is mediated primarily by increased activity of SGLT2 and sodiumhydrogen exchanger isoform 3 (NHE3; Fig. 2 ). This augmented reabsorption reduces the delivery of sodium to the macula densa, which, through tubuloglomerular feedback, causes afferent arteriolar vasodilation and glomerular hyperfiltration [34, 37, 38] . Agents that can attenuate this proximal tubular hyper-reabsorption of sodium have the potential to produce early effects to slow the progression of chronic kidney disease, beyond those that can be produced solely through glycaemic control.
Of the three classes of natriuretic anti-hyperglycaemic drugs, SGLT2 inhibitors exert the most pronounced effect in interfering with sodium reabsorption in the proximal tubule (Fig. 2) , as is evidenced by their ability to cause volume depletion and haemoconcentration in clinical trials [15, 16] . These agents not only inhibit SGLT2 directly, but they also antagonize the activity of NHE3 in the early proximal tubule [39, 40] , which potentiates the ability of these drugs to deliver sodium to the macula densa and ameliorate glomerular hyperfiltration. By comparison, GLP-1 receptor agonists also exert natriuretic effects in the proximal tubule through an action on NHE3 but they do not act on SGLT2 [41] , and thus, their effect to inhibit proximal tubular sodium reabsorption is less pronounced than with SGLT2 inhibitors; treatment with long-acting GLP-1 receptor agonists does not lead to haemoconcentration [10, 11] . In sharp contrast to the two other drug classes, DPP-4 inhibitors have only a minor action on the proximal tubule (mediated through SDF-1 and not by endogenous GLP-1), which may be attenuated in diabetes [5, 42] . The primary natriuretic effect of DPP-4 inhibitors (if any) takes place in the distal tubule (beyond the macula densa), and thus, it cannot use tubuloglomerular feedback to modulate glomerular hyperfiltration [5] . The pronounced effect of SGLT2 inhibitors on sodium reabsorption in the proximal tubule and on glomerular hyperfiltration may explain the early ability of SGLT2 inhibitors to reduce the risk of progression of diabetic kidney disease [15, 32] . In contrast, the lack of an important natriuretic action in the proximal tubule may explain why DPP-4 inhibitors slightly accelerate the rate of decline in GFR and fail to reduce the risk of serious adverse renal events [16, 31] . These differences cannot be ascribed to differences in glycaemic control because, in large-scale trials, both SGLT2 inhibitors and DPP-4 inhibitors lowered HbA 1c to a similar degree and for a similar duration of time [15] [16] [17] [18] .
The finding that treatment with DPP-4 inhibitors for 3-4 years reduces albuminuria but does not prevent a decline in GFR adds to ongoing doubts that changes in urinary protein excretion in Type 2 diabetes represent a reliable surrogate to predict the action of a drug on the clinical course of diabetic chronic kidney disease [43] . Dual blockade of the reninangiotensin system in people with diabetes reduces the magnitude of albuminuria but adversely affects renal outcomes [44, 45] . Conversely, in patients with chronic heart failure (including those with diabetes), neprilysin inhibition with sacubitril/valsartan reduces HbA 1c levels and exerts favourable long-term effects on renal function [46] , but the drug increases albuminuria [47] . The dissociation between changes in urinary protein excretion and changes in glomerular filtration suggests that, at least for the first 3-5 years of treatment, the determinants of albuminuria in Type 2 diabetes differ from the mechanisms that drive the progressive loss of nephrons.
What benefits can DPP-4 inhibitors provide with respect to the evolution of diabetic nephropathy? Microvesselbound DPP-4 appears to be upregulated in the diabetic kidney and is localized to glomerular podocytes in a manner that is associated primarily with albuminuria [48, 49] ; therefore, the effect of DPP-4 inhibitors of ameliorating albuminuria in clinical trials may be related to an action to minimize hyperglycaemia-induced increases in podocyte protein permeability [27] ; however, even an effect on albuminuria does not appear to be a consistent benefit of short-term therapy with DPP-4 inhibitors [50] . Despite reports of modulation of several histological and biochemical markers of renal injury in experimental models, evidence that DPP-4 inhibitors can attenuate the progressive loss of nephrons in diabetic nephropathy independently of their blood glucose-lowering action is sparse. Because of their minimal effects on the proximal tubule, they are not able to utilize tubuloglomerular feedback to reduce glomerular hyperfiltration and ameliorate its consequences. Any effect that DPP-4 inhibitors have in preventing endstage renal disease is probably mediated through a sustained lowering of blood glucose; therefore, if these drugs are capable of significant nephroprotection, physicians may need to prescribe them and achieve meaningful glycaemic control for a decade or more [28] .
Summary and Conclusions
In conclusion, the three classes of anti-hyperglycaemic drugs that promote natriuresis and lower blood pressure have distinctive early effects on both macrovascular and microvascular risk. During the first 3-4 years of treatment, SGLT2 inhibitors have the most favourable effects in reducing the risk of cardiovascular death, slowing the decline in glomerular function and minimizing the risk of serious adverse renal events. By comparison, GLP-1 receptor agonists reduce the risk of myocardial infarction and stroke and modestly slow the rate of deterioration in renal function. DPP-4 inhibitors, by contrast, do not influence macrovascular risk, slightly accelerate the rate of decline in GFR, and do not retard the progression of renal disease. These contrasting profiles cannot be predicted by the effects of these drugs on blood glucose or blood pressure.
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